Focused On-demand Library for Signal peptidase complex catalytic subunit SEC11C

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q9BY50

UPID:
SC11C_HUMAN

ALTERNATIVE NAMES:
Microsomal signal peptidase 21 kDa subunit; SEC11 homolog C; SEC11-like protein 3; SPC21

ALTERNATIVE UPACC:
Q9BY50; B2RAA3

BACKGROUND:
SEC11C, known under various names such as Microsomal signal peptidase 21 kDa subunit and SEC11-like protein 3, is integral to the signal peptidase complex (SPC). It executes the cleavage of N-terminal signal sequences from nascent proteins, a critical step in their translocation into the endoplasmic reticulum. This action ensures proteins are correctly processed for their intended functions within the cell, with a specificity for signal peptides that possess a hydrophobic alpha-helix of less than 18-20 amino acids in length.

THERAPEUTIC SIGNIFICANCE:
The exploration of Signal peptidase complex catalytic subunit SEC11C's function offers a promising avenue for the development of novel therapeutic approaches. Given its essential role in the early stages of protein synthesis and processing, targeting SEC11C could provide new strategies for treating conditions associated with protein folding disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.